Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation
Personalized Medicine for Long QT Syndrome
Zhu, Wandi; Mazzanti, Andrea; Voelker, Taylor L.; Hou, Panpan; Moreno, Jonathan D.; Angsutararux, Paweorn; Naegle, Kristen M.; Priori, Silvia G.; Silva, Jonathan R.
Rationale: Mutations in the SCN5A gene, encoding the alpha subunit of the Nav1.5 channel,
cause a life-threatening form of cardiac arrhythmia, long QT syndrome type 3 (LQT3).
Mexiletine, which is structurally related to the Na+ channel-blocking anesthetic lidocaine,
is used to treat LQT3 patients. However, the patient response is variable, depending
on the genetic mutation in SCN5A.
